RU2224753C2 - Кристаллическая форма 2n-(4-фторметилфенил)-5-метил-изоксазол-4-карбоксамида и способы получения кристаллических форм 1 и 2 указанного карбоксамида - Google Patents

Кристаллическая форма 2n-(4-фторметилфенил)-5-метил-изоксазол-4-карбоксамида и способы получения кристаллических форм 1 и 2 указанного карбоксамида Download PDF

Info

Publication number
RU2224753C2
RU2224753C2 RU98115390/04A RU98115390A RU2224753C2 RU 2224753 C2 RU2224753 C2 RU 2224753C2 RU 98115390/04 A RU98115390/04 A RU 98115390/04A RU 98115390 A RU98115390 A RU 98115390A RU 2224753 C2 RU2224753 C2 RU 2224753C2
Authority
RU
Russia
Prior art keywords
organic solvent
water
crystalline form
formula
mixture
Prior art date
Application number
RU98115390/04A
Other languages
English (en)
Russian (ru)
Other versions
RU98115390A (ru
Inventor
Хольгер ФААШ (DE)
Хольгер ФААШ
Удо ХЕДТМАН (DE)
Удо ХЕДТМАН
Уве ВЕСТЕНФЕЛЬДЕР (DE)
Уве ВЕСТЕНФЕЛЬДЕР
Эрих ПАУЛУС (DE)
Эрих ПАУЛУС
Original Assignee
Авентис Фарма Дойчланд Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19734438A external-priority patent/DE19734438A1/de
Priority claimed from DE1997156093 external-priority patent/DE19756093A1/de
Application filed by Авентис Фарма Дойчланд Гмбх filed Critical Авентис Фарма Дойчланд Гмбх
Publication of RU98115390A publication Critical patent/RU98115390A/ru
Application granted granted Critical
Publication of RU2224753C2 publication Critical patent/RU2224753C2/ru

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D261/00Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/18Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/14Decongestants or antiallergics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
RU98115390/04A 1997-08-08 1998-08-07 Кристаллическая форма 2n-(4-фторметилфенил)-5-метил-изоксазол-4-карбоксамида и способы получения кристаллических форм 1 и 2 указанного карбоксамида RU2224753C2 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE19734438.0 1997-08-08
DE19734438A DE19734438A1 (de) 1997-08-08 1997-08-08 Kristallform von N-(4-Trifluormethylphenyl)-5-methyl-isoxazole-4-carboxamid
DE19756093.8 1997-12-17
DE1997156093 DE19756093A1 (de) 1997-12-17 1997-12-17 Verfahren zur Herstellung einer Kristallform von N-(4-Trifluormethylphenyl)-5-methyl-isoxazole-4-carboxamid

Publications (2)

Publication Number Publication Date
RU98115390A RU98115390A (ru) 2000-08-20
RU2224753C2 true RU2224753C2 (ru) 2004-02-27

Family

ID=26038983

Family Applications (1)

Application Number Title Priority Date Filing Date
RU98115390/04A RU2224753C2 (ru) 1997-08-08 1998-08-07 Кристаллическая форма 2n-(4-фторметилфенил)-5-метил-изоксазол-4-карбоксамида и способы получения кристаллических форм 1 и 2 указанного карбоксамида

Country Status (28)

Country Link
US (5) US6060494A (https=)
EP (2) EP0903345B1 (https=)
JP (2) JPH11124372A (https=)
KR (2) KR100544041B1 (https=)
CN (2) CN1089759C (https=)
AR (1) AR015418A1 (https=)
AT (2) ATE196764T1 (https=)
AU (1) AU752764B2 (https=)
BR (1) BR9806568A (https=)
CA (1) CA2245267C (https=)
CZ (3) CZ301426B6 (https=)
DE (2) DE59801792D1 (https=)
DK (2) DK0987256T3 (https=)
ES (2) ES2150808T3 (https=)
GR (1) GR3034814T3 (https=)
HK (1) HK1049481B (https=)
HU (2) HU229232B1 (https=)
ID (1) ID20667A (https=)
IL (1) IL125671A (https=)
NO (1) NO310871B1 (https=)
NZ (1) NZ331270A (https=)
PL (1) PL192126B1 (https=)
PT (2) PT987256E (https=)
RU (1) RU2224753C2 (https=)
SK (2) SK285216B6 (https=)
TR (2) TR199801513A2 (https=)
TW (1) TW593288B (https=)
UA (1) UA54411C2 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE196764T1 (de) * 1997-08-08 2000-10-15 Aventis Pharma Gmbh Kristallform von 5-methylisoxazol-4-carbonsäure- (4-trifluormethyl)-anilid
DE19908527C2 (de) 1999-02-26 2001-08-30 Aventis Pharma Gmbh Verfahren zur Kristallisation von N-(4-Trifluormethylphenyl)-5-methyl-isoxazol-4-carboxamid
CN1411373A (zh) * 1999-12-16 2003-04-16 特瓦制药工业有限公司 制备来氟米特的新方法和新晶形的来氟米特
CA2400290A1 (en) * 2000-02-15 2001-08-23 Teva Pharmaceutical Industries Ltd. A method for synthesizing leflunomide
CA2429426A1 (en) * 2000-11-17 2002-05-23 Takeda Chemical Industries, Ltd. Isoxazole derivatives
GB0123571D0 (en) 2001-04-05 2001-11-21 Aventis Pharm Prod Inc Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis
US7429593B2 (en) 2001-09-14 2008-09-30 Shionogi & Co., Ltd. Utilities of amide compounds
AU2003207055A1 (en) * 2002-02-12 2003-09-04 Sumitomo Pharmaceuticals Co., Ltd. Novel drugs for external use
US20050158371A1 (en) * 2002-02-12 2005-07-21 Sumitomo Pharmaceuticals Co., Ltd. Novel external agent
US20060135547A1 (en) * 2003-03-12 2006-06-22 Toth Zoltan G Stable pharmaceutical compositions of desloratadine and processes for preparation of polymorphic forms of desloratadine
WO2004080461A2 (en) * 2003-03-12 2004-09-23 TEVA Gyógyszergyár Részvénytársaság Stable pharmaceutical compositions of desloratadine
JP4223428B2 (ja) * 2004-03-31 2009-02-12 富士通メディアデバイス株式会社 フィルタおよびその製造方法
WO2007067710A1 (en) * 2005-12-08 2007-06-14 Amphora Discovery Corporation Certain chemical entities, compositions, and methods for modulating trpv1
CN101143834B (zh) * 2006-09-15 2010-09-08 欣凯医药化工中间体(上海)有限公司 N-(4-三氟甲基苯)-2-氰基-3-羟基丁烯酰胺钠盐的多晶型及其制备方法
JP2011513202A (ja) * 2008-03-10 2011-04-28 武田薬品工業株式会社 ベンズイミダゾール化合物の結晶
US20120172427A1 (en) 2009-09-18 2012-07-05 Sanofi (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide tablet formulations with improved stability
CN103977594B (zh) * 2014-06-03 2016-02-17 江苏九九久科技股份有限公司 一种结晶方法
US9895370B2 (en) * 2015-11-19 2018-02-20 Pharmedix.Co., Ltd Pharmaceutical composition for preventing or treating of cirrhosis of liver comprising G protein coupled receptor 119 ligand as an active ingredient
CN109180599A (zh) * 2018-09-03 2019-01-11 深圳市新阳唯康科技有限公司 一种来氟米特新晶型化合物及其制备方法
CN112898215B (zh) * 2021-02-04 2022-11-08 美罗药业股份有限公司 一种来氟米特晶型i的制备方法
CN114716388B (zh) * 2021-11-04 2024-02-13 江苏冠军科技集团股份有限公司 一种磺胺-银化合物及其制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4284786A (en) * 1978-12-16 1981-08-18 Hoechst Aktiengesellschaft 5-Methylisoxazole-4-carboxylic-(4-trifluoromethyl)-anilide
US4935434A (en) * 1988-01-26 1990-06-19 Bristol-Myers Company Antiarthritic isoxazole-4-carboxamides
RU2060251C1 (ru) * 1991-07-17 1996-05-20 Рон Пуленк Эгрикалчер Лтд. Производные 5-арилизоксазола, способы их получения, гербицидная композиция и способ подавления сорняков в локусе

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL186239B (nl) * 1975-06-05 Hoechst Ag Werkwijze voor de bereiding van een geneesmiddel met antiflogistische en/of analgetische werking, alsmede werkwijze voor de bereiding van een 2-hydroxyethylideencyaanazijnzuuranilide geschikt voor toepassing bij deze werkwijze.
NL178596C (nl) * 1975-06-05 1986-04-16 Hoechst Ag Werkwijze voor het bereiden van een geneesmiddel met antiflogistische en/of analgetische werking, alsmede werkwijze voor het bereiden van daarin als geneeskrachtige verbindingen te gebruiken 5-methylisoxazool-4-carbonzuuraniliden.
DE2524959C2 (de) * 1975-06-05 1983-02-10 Hoechst Ag, 6000 Frankfurt 5-Methyl-isoxazol-4-carbonsäureanilide, Verfahren zu ihrer Herstellung, diese Verbindungen enthaltende Mittel
DE2525959A1 (de) * 1975-06-11 1977-02-10 Focke Pfuhl Verpack Automat Verpackung fuer zigaretten, zigarillos etc.
IL63968A (en) * 1980-10-01 1985-10-31 Glaxo Group Ltd Form 2 ranitidine hydrochloride,its preparation and pharmaceutical compositions containing it
US5583150A (en) * 1989-08-18 1996-12-10 Alcon Laboratories, Inc. 5-methyl-isoxazole-4-carboxylic acid anilides and 2-hydroxyethylidene-cyano acetic anilides for the treatment of ocular diseases
DE59010701D1 (de) * 1990-05-18 1997-05-22 Hoechst Ag Isoxazol-4-carbonsäureamide und hydroxyalkyliden-cyanessigsäureamide, diese verbindungen enthaltende arzneimittel und deren verwendung
DE4127737A1 (de) * 1991-08-22 1993-02-25 Hoechst Ag Arzneimittel zur behandlung von abstossungsreaktionen bei organverpflanzungen
GB9209330D0 (en) * 1992-04-30 1992-06-17 Roussel Lab Ltd Chemical compounds
ES2124800T3 (es) * 1993-01-08 1999-02-16 Hoechst Ag Empleo de leflunomida para la inhibicion de interleuquina 1 beta.
DE59407414D1 (de) * 1993-01-08 1999-01-21 Hoechst Ag Verwendung von Leflunomid zur Hemmung von Tumornekrosefaktor alpha
EP0607777B1 (de) * 1993-01-08 1998-12-09 Hoechst Aktiengesellschaft Verwendung von Leflunomid zur Hemmung von Interleukin 8
TW314467B (https=) * 1993-03-31 1997-09-01 Hoechst Ag
GB9320299D0 (en) * 1993-10-01 1993-11-17 Roussel Lab Ltd Isoxazole derivatives
US5610173A (en) * 1994-01-07 1997-03-11 Sugen, Inc. Formulations for lipophilic compounds
KR100365064B1 (ko) * 1994-10-17 2003-04-11 훽스트파마슈티칼스앤드케미칼스가부시키가이샤 I형알레르기성질환의예방및치료제
SK283608B6 (sk) * 1995-02-06 2003-10-07 Smithkline Beecham Plc Bezvodý hydrochlorid paroxetínu, spôsob jeho výroby a použitie
DE19539638A1 (de) * 1995-10-25 1997-04-30 Hoechst Ag Die Verwendung von Isoxazol- und Crotonsäureamidderivaten zur Behandlung von Krebserkrankungen
US6316479B1 (en) * 1997-05-19 2001-11-13 Sugen, Inc. Isoxazole-4-carboxamide compounds active against protein tryosine kinase related disorders
HRP980291A2 (en) * 1997-06-16 1999-04-30 Lin-Hua Zhang Crystalline roxifiban
ATE196764T1 (de) * 1997-08-08 2000-10-15 Aventis Pharma Gmbh Kristallform von 5-methylisoxazol-4-carbonsäure- (4-trifluormethyl)-anilid
US6096770A (en) * 1998-08-03 2000-08-01 American Home Products Corporation Anthranilic acid analogs
DE19908527C2 (de) * 1999-02-26 2001-08-30 Aventis Pharma Gmbh Verfahren zur Kristallisation von N-(4-Trifluormethylphenyl)-5-methyl-isoxazol-4-carboxamid
CN1411373A (zh) * 1999-12-16 2003-04-16 特瓦制药工业有限公司 制备来氟米特的新方法和新晶形的来氟米特
CA2400290A1 (en) * 2000-02-15 2001-08-23 Teva Pharmaceutical Industries Ltd. A method for synthesizing leflunomide
US6727272B1 (en) * 2002-07-15 2004-04-27 Unitech Pharmaceuticals, Inc. Leflunomide analogs for treating rheumatoid arthritis

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4284786A (en) * 1978-12-16 1981-08-18 Hoechst Aktiengesellschaft 5-Methylisoxazole-4-carboxylic-(4-trifluoromethyl)-anilide
US4935434A (en) * 1988-01-26 1990-06-19 Bristol-Myers Company Antiarthritic isoxazole-4-carboxamides
RU2060251C1 (ru) * 1991-07-17 1996-05-20 Рон Пуленк Эгрикалчер Лтд. Производные 5-арилизоксазола, способы их получения, гербицидная композиция и способ подавления сорняков в локусе

Also Published As

Publication number Publication date
HK1017681A1 (en) 1999-11-26
TW593288B (en) 2004-06-21
CA2245267C (en) 2008-12-23
CZ301514B6 (cs) 2010-03-31
US20030166945A1 (en) 2003-09-04
NO983632D0 (no) 1998-08-07
IL125671A0 (en) 1999-04-11
KR100544041B1 (ko) 2006-09-18
ES2166205T3 (es) 2002-04-01
HUP9801844A2 (hu) 2000-02-28
JPH11124372A (ja) 1999-05-11
EP0987256B1 (de) 2001-10-17
PL192126B1 (pl) 2006-09-29
TR199801513A3 (tr) 1999-02-22
DE59801792D1 (de) 2001-11-22
HU0700190D0 (en) 2007-05-02
KR20050077498A (ko) 2005-08-02
AR015418A1 (es) 2001-05-02
CN1089759C (zh) 2002-08-28
NZ331270A (en) 2000-04-28
US20040204465A1 (en) 2004-10-14
HU225870B1 (en) 2007-11-28
TR200600582A1 (tr) 2006-08-21
AU7887098A (en) 1999-02-18
EP0903345A1 (de) 1999-03-24
EP0987256A1 (de) 2000-03-22
KR19990023433A (ko) 1999-03-25
NO983632L (no) 1999-02-09
ATE196764T1 (de) 2000-10-15
DE59800287D1 (de) 2000-11-09
DK0903345T3 (da) 2000-10-23
HK1049481A1 (en) 2003-05-16
ATE207065T1 (de) 2001-11-15
SK282641B6 (sk) 2002-10-08
HU9801844D0 (en) 1998-10-28
CZ246898A3 (cs) 1999-02-17
ID20667A (id) 1999-02-11
SK285216B6 (sk) 2006-09-07
CN1181064C (zh) 2004-12-22
BR9806568A (pt) 2000-05-16
PL327901A1 (en) 1999-02-15
ES2150808T3 (es) 2000-12-01
PT987256E (pt) 2002-03-28
PT903345E (pt) 2001-01-31
US6995272B2 (en) 2006-02-07
HUP9801844A3 (en) 2000-04-28
HK1049481B (zh) 2005-07-08
EP0903345B1 (de) 2000-10-04
CZ292943B6 (cs) 2004-01-14
US6060494A (en) 2000-05-09
CA2245267A1 (en) 1999-02-08
NO310871B1 (no) 2001-09-10
US6552202B2 (en) 2003-04-22
GR3034814T3 (en) 2001-02-28
SK105898A3 (en) 1999-02-11
DK0987256T3 (da) 2002-02-11
AU752764B2 (en) 2002-09-26
US6221891B1 (en) 2001-04-24
CN1373126A (zh) 2002-10-09
HU229232B1 (en) 2013-09-30
UA54411C2 (uk) 2003-03-17
TR199801513A2 (xx) 1999-02-22
US6900334B2 (en) 2005-05-31
CZ301426B6 (cs) 2010-02-24
US20030027851A1 (en) 2003-02-06
CN1208034A (zh) 1999-02-17
KR100588254B1 (ko) 2006-06-12
JP2009280604A (ja) 2009-12-03
IL125671A (en) 2002-11-10

Similar Documents

Publication Publication Date Title
RU2224753C2 (ru) Кристаллическая форма 2n-(4-фторметилфенил)-5-метил-изоксазол-4-карбоксамида и способы получения кристаллических форм 1 и 2 указанного карбоксамида
RU98115390A (ru) Кристаллические формы n-(4-трифторметилфенил)-5-метил-изоксазол-4-карбоксамида, способ их получения и лекарственные средства
Liu et al. Trifluoromethylfluorosulfonylation of Unactivated Alkenes Using Readily Available Ag (O2CCF2SO2F) and N‐Fluorobenzenesulfonimide
Vázquez et al. Mechanism‐based fluorogenic trans‐cyclooctene–tetrazine cycloaddition
Scott et al. Clean, efficient syntheses of cyclotriveratrylene (CTV) and tris-(O-allyl) CTV in an ionic liquid
KR950032045A (ko) 비누화된 금잔화 함유수지로부터 얻는 루테인의 분리, 정제 및 재결정방법
Kumar et al. Tandem Cu-catalyzed ketenimine formation and intramolecular nucleophile capture: Synthesis of 1, 2-dihydro-2-iminoquinolines from 1-(o-acetamidophenyl) propargyl alcohols
Hoffman et al. Preparation of. alpha.-Alkoxy Amides and. alpha.-Hydrazino Amides by Base-Promoted Reactions of N-Sulfonyloxy Amides
BR122019023690B1 (pt) método para a produção industrial de 2-halo-4,6-dialcoxi-1,3,5-triazina e seu uso na presença de aminas
EA004244B1 (ru) Новый стабильный кристалл производного тиазолидиндиона и способ его получения
BR112017025180B1 (pt) Processo para preparar boscalida
Butcher et al. Synthesis of ar-nitrostyrenes
KR20140108222A (ko) 결정질 형태의 신속한 식별 및 제조를 위한 방법
Chavez et al. Solubility and pseudopolymorphic transitions in mixed solvents: sodium naproxen in methanol− water and ethanol− water solutions
BR112018068688B1 (pt) Processo para converter enantiômero s em sua forma racêmica, composto e uso do mesmo
BR112013011418B1 (pt) Derivado de pirazino[2,3-d]isoxazol, métodos para a produção de um derivado de pirazino [2,3-d]isoxazol e compostos
RU2018114512A (ru) Способ получения соединений индолина и новая соль индолина
JPS6097052A (ja) シアノヒドリン化触媒
JPH0745509B2 (ja) ニッケル錯体
Jereb et al. Direct α-iodination of aryl alkyl ketones by elemental iodine activated by 1-chloromethyl-4-fluoro-1, 4-diazoniabicyclo [2.2. 2] octane bis (tetrafluoroborate)
Sim et al. Synthesis, characterization and differentiation of the structural isomers of valine and tert‐leucine derived synthetic cannabinoids
SU1745717A1 (ru) Способ извлечени флороглюцина из водных растворов
JPH1112259A (ja) イソチアゾロン無水物の製造方法
RU2003113322A (ru) Производное эритромицина, имеющее новые кристаллические структуры, и способы их получения
RU2750297C1 (ru) Производные 1-(3-трет-бутил-4-гидрокси-8-метилпиразоло[5,1-с][1,2,4]триазин-1(4Н)-ил)-2,2-дифторэтанонов, способ их получения и их применение в качестве фотогенераторов кислоты

Legal Events

Date Code Title Description
PD4A Correction of name of patent owner